Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of C402-CD19-CAR, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Targeting CD19 in Subjects With Relapsed or Refractory Large B-cell Lymphoma

NCT06830031 is registered in ClinicalTrials.gov with Shanghai Exuma Biotechnology Ltd. as lead sponsor.

NCT NCT06830031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06830031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of C402-CD19-CAR, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Targeting CD19 in Subjects With Relapsed or Refractory Large B-cell Lymphoma
Lead sponsor
Shanghai Exuma Biotechnology Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
March 25, 2025
Completion date
September 18, 2029
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell-lymphoma, dlbcl, nos genetic subtypes, follicular lymphoma grade 3b, hgbl with myc and bcl2 and/or bcl6 rearrangements, hgbl, nos, pmbl